BMEA BioMea Fusion, Inc.
BioMea Fusion, Inc. (BMEA) is expected to report earnings on November 4, 2026, after the market close. The consensus earnings estimate is a loss of $0.21 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +5.6% since its last earnings release on August 5, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About BioMea Fusion, Inc.
Biomea Fusion Inc. is a clinical-stage diabetes and obesity medicines company focused on the development of its oral small molecules, icovamenib and BMF-650. Biomea Fusion Inc., formerly known as BLOMEA FUSION, is based in Redwood City, California.
Sector
Healthcare
Industry
Biotechnology